Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Summary
The New York Affordable Drug Manufacturing Act aims to enhance the availability and affordability of generic prescription drugs in New York. The bill mandates the state's health commissioner to form partnerships with various entities to produce and distribute generic drugs, thereby increasing market competition and addressing shortages. It emphasizes the need for these drugs to be offered at transparent prices without unnecessary rebates, ultimately benefiting public and private purchasers, taxpayers, and consumers.
Impact
If enacted, this legislation will amend the public health law to establish a framework for the state to directly engage in the production and distribution of generic drugs. This could lead to significant changes in how prescription drugs are procured and priced in New York, potentially lowering costs and improving access for patients, particularly those with chronic conditions or high-cost medication needs.
Sentiment
The sentiment surrounding the bill appears to be generally supportive, as it addresses critical issues of drug affordability and accessibility. However, there may be concerns regarding the feasibility of the proposed partnerships and the implications for existing pharmaceutical market dynamics.
Contention
Notable points of contention may arise from pharmaceutical companies concerned about increased competition and potential impacts on their profit margins. Additionally, there may be debates regarding the effectiveness of state involvement in drug manufacturing and distribution, with some stakeholders advocating for market-driven solutions instead.
Same As
Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provides the list to the attorney general to obtain reasons for the cost increases.
An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.